Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

Amidst the ongoing pressure, we are now upgrading Boston Scientific stock from hold to buy. Click here to read why.

Medical device manufacturer Boston Scientific Corp. (NYSE: BSX) is seemingly off to a tough start to the year, as shares have ...

MD+DI Senior Editor Amanda Pedersen explores the urgent need for transparency in medical device reporting, highlighting ...

The battery problems behind a serious recall of Boston Scientific pacemakers have been ongoing for years, according to a New ...

Explore how a 1992 Law & Order episode eerily mirrors Boston Scientific's real-life pacemaker battery issues, raising ...

In patients with atrial fibrillation, those assigned left atrial appendage closure had similar ischemic outcomes and better bleeding outcomes compared with those assigned oral anticoagulation, ...

AFib, an irregular and often very fast heart rhythm, can lead to blood clots in the heart and significantly increase the ...

Claire Cramer, the executive director of quantum science at the University of California, Berkeley, who was in attendance, expressed optimism about the potential of solid-state nuclear clocks: “This ...

But taken together, the requests formed a pattern — one that, in retrospect, traced a regulatory trail that would later reveal unexpectedly high pacemaker battery failure rates, jeopardizing the lives ...